DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/04/3201-98-104$20.00
DMD 32:98-104, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagar, S.
Right arrow Articles by Zimmerman, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagar, S.
Right arrow Articles by Zimmerman, C. L.

METABOLISM OF OPIOIDS IS ALTERED IN LIVER MICROSOMES OF SICKLE CELL TRANSGENIC MICE

Swati Nagar, Rory P. Remmel, Robert P. Hebbel, and Cheryl L. Zimmerman

Departments of Pharmaceutics (S.N., C.L.Z.), Medicinal Chemistry (R.P.R.), and Medicine (R.P.H.), University of Minnesota, Minneapolis, Minnesota

Pain in sickle cell anemia (SCA) is clinically managed with opioid analgesics. There are reports that SCA patients tolerate high doses of these drugs without adequate pain relief. The current study investigated the in vitro hepatic metabolism of opioids in mouse models of sickle cell anemia, with the hypothesis that higher dose requirements in SCA could be explained by an increased metabolism rate of opioids. Various rodent cytochrome P450 substrates, i.e., buprenorphine and codeine, and rodent uridine glucuronosyltransferase substrates, i.e., morphine, buprenorphine, and estradiol, were studied. The three groups used were: 1) control C57BL mice, 2) mice with the human {alpha}-globin and sickle ß-globin transgenes (SC), and 3) mice with the human {alpha}-globin and sickle ß-globin transgenes, and homozygous for the murine {alpha}-globin and heterozygous for the ßmajor-gene knockout (SCKO). In vitro hepatic microsomal incubations were carried out for each substrate, and data were fit to the Michaelis-Menten equation. Morphine formation had a higher Vmax in SCKO microsomes (0.4 ± 0.009 nmol/min · mg; estimate ± S.E.) than controls (0.25 ± 0.007). Morphine-3-glucuronide formation had Vmax estimates of 18.9 ± 0.6, 25.1 ± 0.4, and 27.06 ± 1.1 nmol/min · mg in control, SC, and SCKO microsomes, respectively. The control Vmax for estradiol-3-glucuronide formation was 2-fold greater than in SCKO microsomes. The control Vmax for estradiol 17-glucuronide formation was 3.4- and 2.2-fold greater than in SC and SCKO microsomes. Thus, in vitro metabolism of opioids is altered in SCA mouse models, which may lead to altered clearances of these drugs.


Address correspondence to: Dr. Cheryl L. Zimmerman, College of Pharmacy, University of Minnesota, 308 Harvard St. S.E, Minneapolis, MN 55455. E-mail: zimme005{at}umn.edu




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
O. F. Iwuchukwu and S. Nagar
Resveratrol (trans-Resveratrol, 3,5,4'-Trihydroxy-trans-stilbene) Glucuronidation Exhibits Atypical Enzyme Kinetics in Various Protein Sources
Drug Metab. Dispos., February 1, 2008; 36(2): 322 - 330.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. R. Solomon
Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void
Blood, February 1, 2008; 111(3): 997 - 1003.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. Ung and S. Nagar
Variable Sulfation of Dietary Polyphenols by Recombinant Human Sulfotransferase (SULT) 1A1 Genetic Variants and SULT1E1
Drug Metab. Dispos., May 1, 2007; 35(5): 740 - 746.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Nagar, S. Walther, and R. L. Blanchard
Sulfotransferase (SULT) 1A1 Polymorphic Variants *1, *2, and *3 Are Associated with Altered Enzymatic Activity, Cellular Phenotype, and Protein Degradation
Mol. Pharmacol., June 1, 2006; 69(6): 2084 - 2092.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.